



IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

In re Application of:

Daniel A. Gamache
David P. Bingaman
Michael A. Kapin

Serial No.: 10/660,152 (Conf. #4949)

Filed: September 11, 2003

For: PDE IV INHIBITORS TO TREAT
ANGIOGENESIS

Group Art Unit: 1617

Examiner: Hui, S.

Atty. Dkt. No.: 1814 US

**AMENDMENT and RESPONSE TO FINAL
OFFICE ACTION DATED FEBRUARY 17, 2005**

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as "Express Mail," Mailing Label EV 676 197 905 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

17 May 2005

Date

Barbara McKenzie

Name

Barbara McKenzie

Sir:

This Amendment is filed in response to the Final Official Action mailed February 17, 2005, for which the three-month date for response is May 17, 2005.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Assistant Commissioner is authorized to deduct said fees from Alcon Laboratories Deposit Account No. 01-0682.

Reconsideration of the application is respectfully requested.

There are no **Amendments to the Specification** in this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

There are no **Amendments to the Drawings** in this paper.

Remarks/Arguments begin on page 3 of this paper.

Express Mail EV 676 197 905 US


05-18-05

IFW
AF/1617

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Application Number	10/660,152 (Conf #4949) ✓
Filing Date	11 September 2003
First Named Inventor	Daniel A. GAMACHE et al.
Art Unit	1617
Examiner Name	Hui, S
Attorney Docket Number	1814 US

Total Number of Pages in This Submission

5

1814 US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Card
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Alcon Research, Ltd.		
Signature			
Printed name	Teresa J. Schultz		
Date	Reg. No.	40,526	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Barbara McKenzie	Date	17 May 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Serial No.: 10/660,152 (Conf #4949)

Filed: 11 September 2003

Page 2

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for treating posterior segment neovascularization which comprises, administering a pharmaceutically effective amount of a selective PDE-IV inhibitor, wherein the selective PDE-IV inhibitor is selected from the group consisting of 2-(4-ethoxycarbonylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-pyridazin-3-one, 3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-isopropyl-3H-purine hydrochloride (~~V-11294A~~), 8-methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide (~~D-4418~~), cipamfylline (~~BRL-61063~~), ~~arifo~~ (~~SB-207499~~), and derivatives thereof.

Claim 2 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is age-related macular degeneration.

Claim 3 (previously presented) The method of claim 2, wherein the age-related macular degeneration is exudative age-related macular degeneration.

Claim 4 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is diabetic retinopathy.

Claim 5 (previously presented) The method of claim 4, wherein the diabetic retinopathy is proliferative diabetic retinopathy.

Claim 6 (previously presented) The method of claim 1, wherein the selective PDE-IV inhibitor is administered by oral administration, transdermally, subdermally, intraperitoneally, subcutaneously, transnasally, sublingually, rectally, by topical ocular administration, intravitreally, periocularly, transclerally, retrobulbar administration, sub-tenon injection, or via an intraocular device.